Theralase Advances Sales and Marketing
15 Avril 2014 - 1:00PM
Access Wire
TORONTO, ONTARIO / ACCESSWIRE / April 15, 2014 / Theralase
Technologies Inc. (TSXV: TLT) (TLTFF: OTCBB) announced today that
it is advancing on its sales and marketing mandate through the
hiring of Mr. Derek Small as Director of Sales and Marketing.
Mr. Small has over 15 years of experience in the sale and
marketing of medical devices in Canada and the US. Mr. Small's
background includes growth from $0 to $20 million in annual revenue
in 5 years, with increasing roles and responsibilities as a senior
sales manager of an US based aesthetic laser company.
Under the leadership of Mr. Small, the vision of the Company for
2014 is to grow its Canadian and US sales and marketing through the
hiring of a direct sales force comprised of: Territory Sales
Managers, Inside Sales Representatives and marketing personnel.
Canada will be subdivided into 3 main territories: Western Canada,
Ontario and Eastern Canada, coinciding with the largest Canadian
cities of Vancouver, Calgary, Toronto and Montreal, The US will be
subdivided into 5 main territories: Northeast, Southeast, Midwest,
South and Southwest, coinciding with the largest US cities of New
York, Miami, Chicago, Dallas and Los Angeles.
The vision of the Company for 2015 is to grow its international
revenue through selection and appointment of master distributors
and country- specific distributors, who would retain exclusive
distribution rights in a particular territory in exchange for
meeting and surpassing minimum quarterly and annual revenue
objectives.
Derek Small, Director of Sales and Marketing for Theralase Inc.
stated that, "It is a pleasure to join the Theralase team and to
execute on their vision. Their current therapeutic laser system,
the TLC-1000, is a best-in-class technology that has helped
millions of patients eliminate their pain throughout Canada. I look
forward to growing the sales and marketing team of Theralase over
2014 and 2015 to achieve the Company's strategic quarterly and
annual revenue objectives. The next generation therapeutic laser
and anti-cancer technology that the Company is currently developing
will be the catalyst that launches the Company's revenue into the
stratosphere through this newly minted sales and marketing team.
The opportunity at Theralase bears close relationship to one of my
previous positions, where I dramatically increased the revenue of
the organization through the hiring of top-notch sales and
marketing talent and the launch of world-class technology. I am
confident that I can repeat the same success with Theralase, as
their technology is clearly state-of-the-art."
Roger Dumoulin-White, President and CEO of Theralase
Technologies Inc. stated that, "I am delighted that the Company has
attracted the talents of an accomplished sales professional, with a
strong history of success in significantly increasing medical
device company sales from $0 to $20 million in sales in 5 years.
Derek has been given the mandate from the Company to assemble a
highly skilled team of Territory Sales Managers, Inside Sales
Managers and marketing personnel in 2Q2014 and 3Q2014 to execute on
the Company's vision of dramatically growing revenue in 2014 and
2015. I wish Derek success in his current mandate."
"Theralase is preparing to launch its next generation TLC-2000
biofeedback therapeutic laser technology in 4Q2014 that will
revolutionize the therapeutic laser industry. This new, patented
cold laser technology will provide patient specific treatments that
adapt to a patient's physical characteristics delivering
best-in-class performance in the elimination of pain, inflammation
and acceleration of tissue healing. The medical community and
patients who experience pain have been waiting for a technology of
this efficacy and performance to enter the market. Derek will be in
charge of launching this new technology in Canada and the US in
4Q2014, through his newly assembled sales and marketing team",
Roger Dumoulin-White, President and CEO of Theralase went on to
say.
About Theralase Technologies Inc.
Theralase Technologies Inc. designs, manufactures and markets
patented, superpulsed laser technology used in eliminating pain and
destroying cancer. Theralase technology is safe and effective in
eliminating pain, reducing inflammation and accelerating tissue
regeneration of numerous nerve, muscle and joint conditions.
Theralase is actively developing patented technology that is able
to target and destroy cancers, bacteria and viruses when light
activated.
Additional information is available at www.theralase.com and
www.sedar.com .
This press release contains forward-looking statements, which
reflect the Company's current expectations regarding future events.
The forward-looking statements involve risks and uncertainties.
Actual results could differ materially from those projected herein.
The Company disclaims any obligation to update these
forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchanges) accepts responsibility for the adequacy or
accuracy of this release.
For More Information:
Roger Dumoulin-White
President & CEO
Theralase Technologies Inc.
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225
rwhite@theralase.com
www.theralase.com
SOURCE: Theralase Technologies Inc.
Theralase Technologies (TSXV:TLT)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Theralase Technologies (TSXV:TLT)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024